{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:16:23Z","timestamp":1768306583087,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uterine fibroids are the most common benign tumors of the female reproductive tract and often cause menorrhagia, pelvic pain, and infertility. Ultrasound-guided microwave ablation (MWA) has gained recognition as a minimally invasive, uterus-preserving therapy; however, incomplete ablation may compromise long-term outcomes. This study aimed to evaluate the efficacy and safety of MWA combined with chemical ablation (CA) compared with MWA alone in patients with symptomatic fibroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included women aged 18\u201355 years with imaging-confirmed uterine fibroids treated between January 2021 and December 2024. Patients were allocated to either the MWA+CA group (n=126) or the MWA group (n=108). Both groups underwent ultrasound-guided percutaneous ablation procedures. Treatment efficacy was assessed based on fibroid volume reduction, cure rates, and recurrence. Statistical analyses included independent-samples t-tests for continuous variables and chi-square tests for categorical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both treatment groups showed significant reductions in fibroid volume. The MWA+CA group experienced a more pronounced reduction, with a mean volume decrease from 33.64 \u00b1 8.20 cm\u00b3 to 10.37 \u00b1 2.25 cm\u00b3 (p &amp;lt; 0.001), compared to the MWA group, where the volume decreased from 32.36 \u00b1 7.18 cm\u00b3 to 15.36 \u00b1 3.27 cm\u00b3 (p &amp;lt; 0.001). The overall effective rate in the MWA+CA group was 98.4%, significantly higher than the 88.9% in the MWA group (p = 0.002). Recurrence rates were significantly lower in the MWA+CA group (1.6% vs. 8.3%, p = 0.015).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ultrasound-guided MWA combined with CA is more effective in reducing fibroid volume and preventing recurrence compared to MWA alone. This combination offers a promising treatment option for symptomatic uterine fibroids, with no significant increase in adverse reactions. Larger, multicenter, prospective studies are needed to further validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1708837","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:34:25Z","timestamp":1768286065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of ultrasound-guided microwave ablation combined with chemical ablation for uterine fibroid management"],"prefix":"10.3389","volume":"15","author":[{"given":"Yu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Pei","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/13645706.2019.1668417","article-title":"Percutaneous microwave ablation of uterine fibroids: correlation between shrinkage and trend symptoms","volume":"30","author":"Ierardi","year":"2021","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2154576","DOI":"10.1080\/02656736.2022.2154576","article-title":"Combined transabdominal and transvaginal ultrasound-guided percutaneous microwave ablation of uterine myomas: an effective monitoring technique","volume":"40","author":"Lin","year":"2023","journal-title":"Int J Hyperthermia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmig.2024.07.020","article-title":"Risk factors and prediction nomogram of local regeneration after ultrasound-guided microwave ablation of uterine fibroids","volume":"31","author":"He","year":"2024","journal-title":"J Minim Invasive Gynecol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20220039","DOI":"10.1259\/bjr.20220039","article-title":"Ultrasound-guided percutaneous microwave ablation for uterine fibroids: mid-term local treatment efficiency and associated influencing factors","volume":"95","author":"Li","year":"2022","journal-title":"Br J Radiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2023.2199560","article-title":"Ultrasound-guided microwave, radiofrequency, and high intensity focused ultrasound (HIFU) ablation in treating uterine leiomyoma: A systemic review and meta-analysis of retrospective studies","volume":"40","author":"Fan","year":"2024","journal-title":"Biotechnol Genet Eng Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-023-07334-9","article-title":"Application of transabdominal ultrasound- and laparoscopy-guided percutaneous microwave ablation for treating uterine fibroids: 24-month follow-up outcomes","volume":"309","author":"Chen","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmig.2018.06.014","article-title":"Ultrasound-guided percutaneous microwave ablation for subserosal uterine myomas","volume":"26","author":"Yang","year":"2019","journal-title":"J Minim Invasive Gynecol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2109764","article-title":"Long term follow-up of uterine fibroids treated with microwave ablation: an up to 3-year observational study of volume, regrowth, and symptoms","volume":"39","author":"Beermann","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"113954","DOI":"10.1016\/j.ejogrb.2025.113954","article-title":"Clinical efficacy of percutaneous microwave ablation in treating uterine fibroids: A comprehensive systematic review and meta-analysis","volume":"310","author":"Ahmad","year":"2025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2034991","article-title":"Ultrasound guided microwave ablation compared to uterine artery embolization treatment for uterine fibroids - a randomized controlled trial","volume":"39","author":"Jonsdottir","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2013.853107","article-title":"Uterine myomas treated with microwave ablation: the agreement between ablation volumes obtained from contrast-enhanced sonography and enhanced MRI","volume":"30","author":"Lei","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2021.0202","article-title":"Minimally invasive treatment options for uterine fibroids - state-of-the art 2021","volume":"93","author":"Krzyzanowski","year":"2022","journal-title":"Ginekol Pol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jvir.2023.09.017","article-title":"An evaluation of ultrasound-guided percutaneous microwave ablation for the treatment of symptomatic uterine fibroids","volume":"35","author":"Ahmadzade","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2016.1212276","article-title":"Effectiveness of ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroids: a multicentre study in China","volume":"32","author":"Liu","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.15041","article-title":"Ultrasound guided microwave ablation treatment of uterine fibroids: Clinical response and patient acceptability","volume":"104","author":"Jonsdottir","year":"2025","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-025-05024-5","article-title":"Ultrasound-guided percutaneous microwave ablation assisted by a three-dimensional visualization treatment platform (3DVOPS) for large uterine fibroids","author":"Hai","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i5.980","article-title":"Abnormal uterine bleeding successfully treated via ultrasound-guided microwave ablation of uterine myoma lesions: Three case reports","volume":"12","author":"Kakinuma","year":"2024","journal-title":"World J Clin cases"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-602","article-title":"The safety and efficacy of add-on use of oxytocin in uterine leiomyoma patients undergoing high-intensity focused ultrasound and ultrasound-guided intratumoral ethanol injection: a randomized controlled trial","volume":"11","author":"Zhang","year":"2022","journal-title":"Ann Palliat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00155","article-title":"Locoregional thermal and chemical tumor ablation: review of clinical applications and potential opportunities for use in low- and middle-income countries","volume":"9","author":"Quang","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/medicina60060868","article-title":"Currently available treatment modalities for uterine fibroids","volume":"60","author":"Mici\u0107","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1186\/s12885-023-11301-7","article-title":"Comparison of the effectiveness of lauromacrogol injection for ablation and microwave ablation in the treatment of predominantly cystic thyroid nodules: a multicentre study","volume":"23","author":"Min","year":"2023","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.601977","article-title":"Clinical assessment of ultrasound-guided local lauromacrogol injection combined with curettage and hysteroscopy for cesarean scar pregnancy","volume":"11","author":"Wu","year":"2020","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1053\/j.gastro.2023.01.006","article-title":"Injectable, drug-eluting nanocrystals prevent fibrosis and stricture formation in vivo","volume":"164","author":"Li","year":"2023","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2022.12.006","article-title":"Uterine Myoma Position-based Radiofrequency Ablation (UMP-b RFA): 36 months follow-up clinical outcomes","volume":"281","author":"Fasciani","year":"2023","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2223369","DOI":"10.1080\/02656736.2023.2223369","article-title":"A method to protect the endometrium for microwave ablation treating types 1\u20133 uterine fibroids: a preliminary comparative study","volume":"40","author":"Su","year":"2023","journal-title":"Int J Hyperthermia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1708837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:34:25Z","timestamp":1768286065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1708837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1708837"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1708837","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1708837"}}